Michala Burges

Michala Burges

Auto-generated profile, based on publicly available information

Michala Burges

Department of Ophthalmology, Hamilton Eye Institute, University of Tennessee Health Science Center, College of Medicine, and Department of Oncology, St. Jude Children’s Research Hospital, Memphis, Tennessee

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Ophthalmology
Verified
Journal Article
Open access
ATAnkit Singh Tomar
Ankit Singh Tomar
PFPaul T Finger
Paul T Finger
BGBrenda Gallie
Brenda Gallie
AMAshwin Mallipatna
Ashwin Mallipatna
TKTero T. Kivelä
Tero T. Kivelä
ECElisa Carreras
Elisa Carreras
To evaluate the ability of the 8th edition of the American Joint Committee on Cancer (AJCC) Staging to predict local tumor control and globe salvage for children with retinoblastoma (RB). International, multicenter, registry-based retrospective case series PARTICIPANTS: 2854 eyes of 2097 patients from 18 ophthalmic oncology centers from 13 countries over 6 continents. International, multicenter, registry-based data was pooled from patients enrolled between January 2001-December 2013. All RB eyes with adequate records to allow tumor staging by the AJCC 8th edition criteria and follow-up to ascertain treatment outcomes were included. Globe-salvage rates were estimated by AJCC clinical(cTNMH) categories and tumor laterality. Local treatment failure was defined as use of enucleation or external beam radiation therapy (EBRT), with or without plaque brachytherapy or intra-arterial chemotherapy (IAC). Unilateral RB occurred in 1340 (47%) eyes. Amongst the 2854 eyes, tumor categories were cT1-cT4 in 696 (24%), 1334 (47%), 802 (28%), and 22 (1%) eyes, respectively. Of these, 1275 (45%) eyes were salvaged, and 1179 (41%) and 400 (14%) underwent primary and secondary enucleation, respectively. The 2- and 5-year Kaplan-Meier cumulative globe-salvage rates without use of EBRT by cTNMH categories were 97% and 96% for category cT1a tumors, 94% and 88% for cT1b tumors, 68% and 60% for cT2a tumors, 66% and 57% for cT2b tumors, and 32% and 25% for cT3 tumors respectively. Risk of local treatment failure increased with increasing cT category (p <0.001). Cox proportional hazards regression analysis confirmed a higher risk of local treatment failure in category cT1b (hazard ratio [HR], 3.5; p=0.004), cT2a (HR, 15.1; p< 0.001), cT2b (HR, 16.4; p< 0.001) and cT3 (HR, 45.0; p< 0.001) compared to category cT1a. Use of plaque brachytherapy and IAC improved local tumor control in categories cT1a (p=0.031) and cT1b (p< 0.001). Multicenter, international, internet-based data sharing validated the 8th edition AJCC RB staging to predict globe-salvage in a large, real life, heterogenous, real-world retinoblastoma patient population.

15 April 2022 in Ophthalmology
Verified
Journal Article
Open access
ATAnkit Singh Tomar
Ankit Singh Tomar
PFPaul T Finger
Paul T Finger
BGBrenda Gallie
Brenda Gallie
TKTero T. Kivelä
Tero T. Kivelä
AMAshwin Mallipatna
Ashwin Mallipatna
ECElisa Carreras
Elisa Carreras
To determine the value of clinical features for advanced intraocular retinoblastoma as defined by the eighth edition of the American Joint Committee on Cancer (AJCC) cT3 category and AJCC Ophthalmic Oncology Task Force (OOTF) Size Groups to predict the high-risk pathologic features. International, multicenter, registry-based retrospective case series. Eighteen ophthalmic oncology centers from 13 countries over 6 continents shared evaluations of 942 eyes enucleated as primary treatment for AJCC cT3 and, for comparison, cT2 retinoblastoma. International, multicenter, registry-based data were pooled from patients enrolled between 2001 and 2013. High-risk pathologic features were defined as AJCC categories pT3 and pT4. In addition, AJCC OOTF Size Groups were defined as follows: (1) less than half, (2) more than half but less than two thirds, (3) more than two thirds of globe volume involved, and (4) diffuse infiltrating retinoblastoma. Statistical risk of high-risk pathologic features corresponding to AJCC cT3 subcategories and AJCC OOTF Size Groups. Of 942 retinoblastoma eyes treated by primary enucleation, 282 (30%) showed high-risk pathologic features. Both cT subcategories and AJCC OOTF Size Groups (P < 0.001 for both) were associated with high-risk pathologic features. On logistic regression analysis, cT3c (iris neovascularization with glaucoma), cT3d (intraocular hemorrhage), and cT3e (aseptic orbital cellulitis) were predictive factors for high-risk pathologic features when compared with cT2a with an odds ratio of 2.3 (P = 0.002), 2.5 (P = 0.002), and 3.3 (P = 0.019), respectively. Size Group 3 (more than two-thirds globe volume) and 4 (diffuse infiltrative retinoblastoma) were the best predictive factors with an odds ratio of 3.3 and 4.1 (P < 0.001 for both), respectively, for high-risk pathologic features when compared with Size Groups 1 (i.e., < 50% of globe volume). The AJCC retinoblastoma staging clinical cT3c–e subcategories (glaucoma, intraocular hemorrhage, and aseptic orbital cellulitis, respectively) as well as the AJCC OOTF Size Groups 3 (tumor more than two thirds of globe volume) and 4 (diffuse infiltrative retinoblastoma) both allowed stratification of clinical risk factors that can be used to predict the presence of high-risk pathologic features and thus facilitate treatment decisions.

30 April 2022 in Ophthalmology
Verified
Journal Article
Open access
ATAnkit Singh Tomar
Ankit Singh Tomar
PFPaul T Finger
Paul T Finger
BGBrenda Gallie
Brenda Gallie
TKTero T. Kivelä
Tero T. Kivelä
AMAshwin Mallipatna
Ashwin Mallipatna
ECElisa Carreras
Elisa Carreras
To evaluate presenting features, tumor size, and treatment methods for risk of metastatic death due to advanced intraocular retinoblastoma (RB). International, multicenter, registry-based retrospective case series. A total of 1841 patients with advanced RB. Advanced RB was defined by 8th edition American Joint Committee on Cancer (AJCC) categories cT2 and cT3 and new AJCC-Ophthalmic Oncology Task Force (OOTF) Size Groups (1: < 50% of globe volume, 2: > 50% but < 2/3, 3: > 2/3, and 4: diffuse infiltrating RB). Treatments were primary enucleation, systemic chemotherapy with secondary enucleation, and systemic chemotherapy with eye salvage. Metastatic death. The 5-year Kaplan–Meier cumulative survival estimates by patient-level AJCC clinical subcategories were 98% for cT2a, 96% for cT2b, 88% for cT3a, 95% for cT3b, 92% for cT3c, 84% for cT3d, and 75% for cT3e RB. Survival estimates by treatment modality were 96% for primary enucleation, 89% for systemic chemotherapy and secondary enucleation, and 90% for systemic chemotherapy with eye salvage. Risk of metastatic mortality increased with increasing cT subcategory (P < 0.001). Cox proportional hazards regression analysis confirmed a higher risk of metastatic mortality in categories cT3c (glaucoma, hazard ratio [HR], 4.9; P = 0.011), cT3d (intraocular hemorrhage, HR, 14.0; P < 0.001), and cT3e (orbital cellulitis, HR, 19.6; P < 0.001) than in category cT2a and with systemic chemotherapy with secondary enucleation (HR, 3.3; P < 0.001) and eye salvage (HR, 4.9; P < 0.001) than with primary enucleation. The 5-year Kaplan–Meier cumulative survival estimates by AJCC-OOTF Size Groups 1 to 4 were 99%, 96%, 94%, and 83%, respectively. Mortality from metastatic RB increased with increasing Size Group (P < 0.001). Cox proportional hazards regression analysis revealed that patients with Size Group 3 (HR, 10.0; P = 0.002) and 4 (HR, 41.1; P < 0.001) had a greater risk of metastatic mortality than Size Group 1. The AJCC-RB cT2 and cT3 subcategories and size-based AJCC-OOTF Groups 3 (> 2/3 globe volume) and 4 (diffuse infiltrating RB) provided a robust stratification of clinical risk for metastatic death in advanced intraocular RB. Primary enucleation offered the highest survival rates for patients with advanced intraocular RB.

1 October 2020 in JCO Global Oncology
Verified
Journal Article
Open access
MBMichala Burges
Michala Burges
IQIbrahim Qaddoumi
Ibrahim Qaddoumi
RBRachel C. Brennan
Rachel C. Brennan
LKLisa Krull
Lisa Krull
NSNatasha Sahr
Natasha Sahr
MWMatthew W. Wilson
Matthew W. Wilson
PURPOSE We aimed to evaluate the capacity to treat retinoblastoma in the Middle East, North Africa, and West Asia region. METHODS A Web-based assessment that investigated retinoblastoma-related pediatric oncology and ophthalmology infrastructure and associated capacity at member institutions of the Pediatric Oncology East and Mediterranean group was distributed. Data were analyzed in terms of availability, location, and confidence of use for each resource needed for the management of retinoblastoma. Resources were categorized by diagnostics, focal therapy, chemotherapy, advanced treatment, and supportive care. Responding institutions were further divided into an asset-based tiered system. RESULTS In total, responses from 23 institutions were obtained. Fifteen institutions reported the availability of an ophthalmologist, 12 of which held primary off-site appointments. All institutions reported the availability of a pediatric oncologist and systemic chemotherapy A significant portion of available resources was located off site. Green laser was available on site at seven institutions, diode laser at six institutions, cryotherapy at 12 institutions, and brachytherapy at nine institutions. There existed marked disparity between the availability of some specific ophthalmic resources and oncologic resources. CONCLUSION The assessment revealed common themes related to the treatment of retinoblastoma in low- and- middle-income countries, including decentralization of care, limited resources, and lack of multidisciplinary care. Resource disparities warrant targeted intervention in the Middle East, North Africa, and West Asia region to advance the management of retinoblastoma in the region. (c) 2020 by American Society of Clinical Oncology

10 December 2019 in American Journal of Health Education
Verified
Journal Article
Closed access
Elizabeth HoltElizabeth Holt
Elizabeth Holt
ACA. L. Cass
A. L. Cass
HPH. Park
H. Park
SCS. Criss
S. Criss
MBM. Burges
M. Burges
SMS. Murr
S. Murr
Background: College wellness interventions have potential to reduce the growing burden of cardiovascular disease (CVD) by guiding students to establish behaviors for lifetime CVD risk reduction. Yet, some students may not see CVD prevention as a relevant issue during young adulthood. Purpose: We examined perceived risk of CVD amongst 148 college students and compared perceived risk to demographic characteristics and traditional risk markers. Methods: Survey data on perceived CVD risk and student characteristics were linked to biochemical lab values from a cholesterol screening program. Results: Only 39.2% of students had been previously screened for dyslipidemia. Mean perceived CVD risk was highest amongst students with age ≥21 years, BMI ≥30, a family history of CVD, and a fair or poor rating of overall health. Perceived risk was not higher amongst students with total cholesterol values outside of the normal range. Discussion: While some students were aware they may possess an elevated CVD risk, we identified others who were unaware of a potential risk. Translation to Health Education Practice: These variations in perceived risk indicate that individualized intervention approaches may be necessary to engage college students in behaviors for lifelong CVD prevention.

2 January 2019 in Ophthalmic Genetics
Verified
Journal Article
Closed access
MBMichala Burges
Michala Burges
BKBenjamin King
Benjamin King
RMRose McGee
Rose McGee
RBRachel Brennan
Rachel Brennan
MWMatthew Wilson
Matthew Wilson